Clovis OncologyInc.
Gemcitabine/Cisplatin I(Clovis Oncology, Inc.)은 Muscle Invasive Bladder Urothelial Carci 표적 ADC로, Muscle Invasive Bladder Urothelial Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 45.2% (ClinicalTrials.gov NCT00078949). 차별점: novel FGFR3-targeted antibody-drug conjugate in bladder cancer.
Muscle Invasive Bladder Urothelial Carci
Muscle Invasive Bladder Urothelial Carcinoma
Active
ADC+ICI) versus gemcitabine/cisplatin (GC) in high-risk upper t
vedotin after avelumab
cleavable GGFG linker, and the payload DXD
humanized anti-FGFR3 IgG1 monoclonal antibody, a cleavable GGFG linker, and the payload DXD
novel FGFR3-targeted antibody-drug conjugate in bladder cancer
Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway
macrophages (TAMs) while promoting CD8 + T-cell infiltration and cytotoxicity
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
biomarker-informed trials, rather than to identify a single preferred ICI strategy
resistance mechanisms, along with more recent studies supporting or proposing second-line treatments
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Clovis OncologyInc.
Gemcitabine/Cisplatin I(Clovis Oncology, Inc.)은 Muscle Invasive Bladder Urothelial Carci 표적 ADC로, Muscle Invasive Bladder Urothelial Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 45.2% (ClinicalTrials.gov NCT00078949). 차별점: novel FGFR3-targeted antibody-drug conjugate in bladder cancer.
Muscle Invasive Bladder Urothelial Carci
Muscle Invasive Bladder Urothelial Carcinoma
Active
ADC+ICI) versus gemcitabine/cisplatin (GC) in high-risk upper t
vedotin after avelumab
cleavable GGFG linker, and the payload DXD
humanized anti-FGFR3 IgG1 monoclonal antibody, a cleavable GGFG linker, and the payload DXD
novel FGFR3-targeted antibody-drug conjugate in bladder cancer
Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway
macrophages (TAMs) while promoting CD8 + T-cell infiltration and cytotoxicity
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
biomarker-informed trials, rather than to identify a single preferred ICI strategy
resistance mechanisms, along with more recent studies supporting or proposing second-line treatments
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.